Silver Book Fact

Effectiveness of pneumonia vaccine

PPSV23 (pneumococcal polysaccharide vaccine) protects against 23 types of pneumococcal bacteria and is 60% to 80% effective in preventing pneumococcal bacteremia in adults over the age of 65 who are not immunocompromised.

Ask the Experts: Pneumococcal vaccines. www.immunize.org/askexperts/experts_pneumococcal_vaccines.asp. Published November 1, 2012

Reference

Title
Ask the Experts: Pneumococcal vaccines
Publication Date
Published November 1, 2012
Authors
Immunization Action Coalition
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Vaccines in development 2013
    137 vaccines are currently in development in the U.S. for infectious diseases.  
  • Cost-effectiveness of flu vaccine
    Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Infection control program reduced hospital-acquired HAIs by > 1/3
    A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.